- LOXO-292 New Drug Application (NDA) Submission to FDA Expected in Late 2019 - - Updated Larotrectinib...
STAMFORD, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
FORM 4 [ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
SCHEDULE 13G Amendment No. 3 LOXO ONCOLOGY INC COMMON STOCK Cusip #548862101 Check the appropriate box to designate...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.